Lumicell

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Lumicell, Health/Medical/ Pharmaceuticals, 275 Washington St., Suite 200, Newton, MA.

Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs.

07/07/2025

What if the surgeon had the power to see residual breast cancer during surgery and remove it in real-time? Listen to Jennifer Montes, MD, MPH, Breast Surgeon and President, Evolve Pink, paid consultant of Lumicell, share her perspective on the potential of LumiSystem™.

LumiSystem is the first and only solution for use in adult patients with breast cancer to assist surgeons in the detection of cancerous tissue within the lumpectomy cavity following removal of the primary specimen during lumpectomy surgery. LUMISIGHT (pegulicianine) and Lumicell™ Direct Visualization System (DVS) enable surgeons to detect and resect residual cancer, in real-time.

Learn more about LumiSystem: https://lumisystem.com/ #

The most common side effects with LUMISIGHT are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For Important Safety Information and complete product information, visit www.LumiSystem.com.

, ,

04/28/2025

Thank you, Dr. Andrew Chan and Dr. David Drew, for presenting our promising feasibility trial findings in gastrointestinal cancer patients at AACR 2025.

Lumicell's imaging research was discussed during the Stand Up To Cancer (SU2C) open Scientific Session "Advances in Detection and Treatment of Gastrointestinal Cancers" today (Monday, April 28).

Read our release at https://lumicell.com/news-press/

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this press release reflect Lumicell’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions, and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the regulatory process to approve pharmaceutical drugs or medical devices. Indication expansion involving gastrointestinal cancers require additional studies and FDA approval.

03/03/2025

Despite surgical advancements, up to 36% of patients require a second lumpectomy because cancer may have gone undetected.¹ However, when these second surgeries are performed, cancer is not found in up to 65% of cases.¹ This leaves patients and surgeons uncertain about the possibility of cancer remaining in the breast. Uncertainty persists even for patients who receive a report of negative margins following the initial surgery, with approximately 14% of them possibly still having cancer remaining.¹

LumiSystemᵀᴹ represents a promising advancement in surgical imaging technology that can be added to the lumpectomy procedure. Clinically proven to detect cancer that otherwise would have been missed, LumiSystem helps reduce the need for follow-up surgeries by detecting residual cancer in real-time. This capability not only spares some patients from additional procedures, but also informs the surgeon of the presence of cancer not initially detected in patients that would otherwise have had negative margins.

Learn more about LumiSystem: https://lumisystem.com/

Ask your doctor if LumiSystem is right for you.

The most common side effects with LUMISIGHTᵀᴹ (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicellᵀᴹ DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For complete product information, visit www.LumiSystem.com.

1. Dupont, et al. Ann Surg 2021.

, ,

02/18/2025

With 84% diagnostic accuracy, LumiSystem™ improved surgical outcomes in 10% of patients treated in the INSITE pivotal trial.¹⁻² By identifying cancerous tissue that would have been missed, LumiSystem offers a more comprehensive approach to breast-conserving surgery and ultimately enhances patient care. LumiSystem is used in addition to the standard of care lumpectomy.

Learn more about LumiSystem: https://lumisystem.com/

Ask your doctor if LumiSystem is right for you.

The most common side effects with LUMISIGHT™ (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell™ DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For complete product information, visit www.LumiSystem.com.

1. Diagnostic accuracy is based on true positive and true negative images detected in the LumiSystem pivotal trial
2. Smith, et al., NEJM Evidence 2023; 2(7)

, ,

02/03/2025

Lumicell’s innovative surgical imaging technology has been featured in USA Today®. Learn more about this technology and visit LearnAboutLumicell.com.

Read the full article here: https://www.usatoday.com/story/sponsor-story/lumicell-bh/2024/12/18/advances-in-breast-cancer-surgery-offer-patients-improved-surgical-outcomes/77048294007/

01/27/2025

We are proud to announce the U.S. commercial availability and first clinical use of LumiSystem™, the first and only fluorescence-guided imaging technology used during surgery for detection of residual breast cancer. This innovative system represents a significant advancement in breast-conserving surgery, enabling surgeons to achieve more complete resections and improve patient surgical outcomes.

For more information about LumiSystem™ and its capabilities, visit https://lumisystem.com/

Read the Press Release: https://lumicell.com/news-press/

The most common side effects with LUMISIGHT™ (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For complete product information, visit www.LumiSystem.com.

01/06/2025

Lumicell is pleased to announce the appointment of Jim Alecxih to its Board of Directors.

“We’re excited to welcome Jim to our Board of Directors. His extensive commercial and operational experience, along with a proven track record of success, will be invaluable to Lumicell,” said Howard Hechler, Chief Executive Officer of Lumicell. “Jim’s deep experience in the healthcare industry and diagnostic imaging aligns seamlessly with Lumicell’s mission to advance cancer detection across the continuum of solid tumors and improve surgical outcomes.”

Read the press release: https://lumicell.com/news-press/

12/13/2024

At SABCS 2024, Lumicell presented new data focused on patient benefit of using LumiSystem™ during lumpectomy. The findings suggest that patient satisfaction with cosmetic outcomes did not change following fluorescence-guided tissue removal and showed a strong preference for avoiding second surgeries. Additionally, adding LumiSystem to a lumpectomy procedure may alter radiation therapy recommendations in a subset of patients.

"The response from both the health care community and patients has been very positive as we have initiated our commercial launch of LumiSystem,” said Howard Hechler, Chief Executive Officer at Lumicell.

Read the Press Release: https://lumicell.com/news-press/

The most common side effects with LUMISIGHT™ (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell™ DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For complete product information, visit www.LumiSystem.com.

, ,

11/20/2024

Lumicell™ has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code for Hospital Outpatient Prospective Payment System (OPPS) by the Centers for Medicare & Medicaid Services (CMS) for its innovative optical imaging agent, LUMISIGHT™ (pegulicianine), for fluorescence-guided lumpectomy surgery.

“This code will help patients with breast cancer and surgeons gain access to our technology that's been clinically proven to find cancer that otherwise would have been missed during a lumpectomy procedure,” said Howard Hechler, Chief Executive Officer.

Read the Press Release: https://lumicell.com/news-press/

The most common side effects with LUMISIGHT™ (pegulicianine) are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Please see the LUMISIGHT Prescribing Information (https://lumisystem.com/prescribing-information/), including Boxed Warning, and Lumicell DVS Instructions for Use (https://lumisystem.com/instructions-for-use/). For complete product information, visit www.LumiSystem.com.

, ,

11/18/2024

Lumicell is pleased to announce the appointment of Howard Hechler as Chief Executive Officer.

“The Board of Directors unanimously voted to appoint Howard as Lumicell’s CEO, based upon the crucial role he played in leading Lumicell through our FDA-approval process and preparing for the ongoing commercial launch,” said Andrey Zarur, PhD, Executive Chairman, Lumicell, and CEO, Green Light Biosciences. “We are confident in his ability to drive deep and sustained market adoption of Lumicell’s recently approved technology into their lead indication, as well as expand the platform into many other solid tumor indications.”

Hechler joined Lumicell in 2020 as Senior Vice President of Strategy & Business Development, bringing over 20 years of life-science experience in corporate development, strategy, and operations. He was first promoted to Chief Business & Strategy Officer in 2022, and then took on the additional responsibilities of COO and President in December of 2023.

Prior to Lumicell, Hechler worked at Locust Walk, PolarityTE, Smith & Nephew, Medtronic, and Mallinckrodt Pharmaceuticals. He graduated cm laude with a bachelor’s degree from Harvard University and received his M.B.A and juris doctorate from the University of Virginia.

Read the press release: https://lumicell.com/news-press/

11/01/2024

The Lumicell team and their families participated in the 2024 Susan G. Komen walk to support the mission of ending breast cancer and the mission to improve access to quality breast cancer screening, diagnosis and treatment for all.

10/29/2024

We are excited to share that during this Breast Cancer Awareness Month, Viewpoint with Dennis Quaid has featured Lumicell's cutting-edge technology.

To watch the video, click the following link and then press the 'play' button: https://www.viewpointproject.com/features-postid999a1e10/

To learn more, visit LearnAboutLumicell.com

Address

275 Washington St., Suite 200
Newton, MA
02458

Telephone

+16174041001

Website

http://www.lumicell.com/, http://www.LearnAboutLumicell.com/

Alerts

Be the first to know and let us send you an email when Lumicell posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Newton?